Reuters logo
BRIEF-Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients
September 19, 2017 / 10:46 AM / a month ago

BRIEF-Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients

Sept 19 (Reuters) - Prometic Life Sciences Inc

* Prometic Life Sciences Inc - ‍clinical study has now enrolled 12 subjects​

* Prometic Life Sciences Inc - ‍DSMB and MHRA have allowed for 2 successive extensions of duration of treatment​

* Prometic Life Sciences - ‍duration of treatment extended from original 24 weeks for additional 36 weeks, and then once more for further 12 weeks​

* Prometic Life Sciences Inc - ‍sustained safety observed over 48 weeks of treatment​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below